New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 6, 2013
18:25 EDTALNYAlnylam introduces a new ‘Alnylam 5x15’ program – ALN-AS1
Alnylam introduces a new ‘Alnylam 5x15’ program – ALN-AS1 for the treatment of acute intermittent porphyria, an ultra-rare genetic disease caused by loss of function mutations in an enzyme in the heme biosynthesis pathway that result in acute and/or recurrent life-threatening attacks with severe abdominal pain, peripheral and autonomic neuropathy, and neuropsychiatric manifestations. In aggregate, we believe that execution on our ‘Alnylam 5x15’ programs and our ambitious goals for 2013 and beyond will enable continued advancement of RNAi therapeutics as innovative medicines for patients, resulting in value creation for our shareholders.”
News For ALNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
08:01 EDTALNYAlnylam announces planned departure of Chief Business Officer
Subscribe for More Information
December 18, 2014
08:09 EDTALNYAlnylam names Cubist CEO Michael Bonney to board of directors
Subscribe for More Information
December 15, 2014
08:42 EDTALNYAlnylam price target raised to $125 from $105 at Leerink
Subscribe for More Information
06:06 EDTALNYAlnylam price target raised to $158 from $134 at Piper Jaffray
Subscribe for More Information
December 12, 2014
10:01 EDTALNYOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:05 EDTALNYAlnylam sees filing IND for ALN-HBV DC program in late 2015
Subscribe for More Information
07:03 EDTALNYAlnylam sees initial data from ALN-PCSsc trial in mid-2015
Subscribe for More Information
07:02 EDTALNYAlnylam updates guidance to file clinical trial application for ALN-AS1
Subscribe for More Information
05:30 EDTALNYAlnylam initiated with a Neutral at Goldman
Goldman started shares of Alnylam Pharmaceuticals with a Neutral rating and $113 price target saying it prefers to wait for a more favorable entry point into the name.
December 11, 2014
16:02 EDTALNYAlnylam initiates ENDEAVOUR Phase 3 clinical trial with revusiran
Subscribe for More Information
08:02 EDTALNYAlnylam, The Medicines Co. announce initiation of Phase 1 ALN-PCSsc trial
Subscribe for More Information
December 9, 2014
12:22 EDTALNYPiper Jaffray biopharm analyst holds an analyst/industry conference call
Senior Research Analyst Schimmer, along with Biopharmaceuticals Analyst Breazzano, discuss gene therapy for hemophilia on an Analyst/Industry conference call to be held on December 11 at 10 am.
06:38 EDTALNYAlnylam to host conference call
Conference call to discuss Phase 1 data from ALN-AT3, in development for the treatment of hemophilia will be held on December 9 at 8 am. Webcast Link
05:47 EDTALNYAlnylam reports poisitve initial results for ALN-AT3
Subscribe for More Information
December 7, 2014
13:13 EDTALNYAlnylam files clinical trial application for ALN-CC5
Alnylam Pharmaceuticals announced that it has filed a Clinical Trial Application, CTA, with the U.K. Medicines and Healthcare products Regulatory Agency, MHRA, to initiate a Phase 1/2 clinical trial with ALN-CC5, a subcutaneously administered investigational RNAi therapeutic targeting complement component C5 for the treatment of complement-mediated diseases. As per the CTA filing, the intended clinical study of ALN-CC5 will be performed in normal human volunteers and, then, in patients with paroxysmal nocturnal hemoglobinuria, PNH. Following approval of the CTA, the company expects to initiate the Phase 1/2 study in early 2015, with initial data expected to be reported in mid-2015. In addition, Alnylam scientists presented new pre-clinical data at the 56th Annual Meeting of the American Society of Hematology. Amongst other reported research findings, new data showed an up to 99.2% knockdown of serum C5 and up to 96.2% inhibition of serum hemolytic activity in non-human primates, NHPs, with continued dosing for over seven months.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use